RT Journal Article
SR Electronic
T1 Natriuretic Peptides Improve Classification of People at Low Risk of Atrial Fibrillation after Stroke
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.28.23296282
DO 10.1101/2023.09.28.23296282
A1 Cameron, Alan
A1 Arnold, Markus
A1 Katsas, Georgios
A1 Yang, Jason
A1 Quinn, Terence J
A1 Abdul-Rahim, Azmil H
A1 Campbell, Ross
A1 Docherty, Kieran
A1 De Marchis, Gian Marco
A1 Arnold, Marcel
A1 Kahles, Timo
A1 Nedeltchev, Krassen
A1 Cereda, Carlo
A1 Kaegi, Georg
A1 Bustamante, Alejandro
A1 Montaner, Joan
A1 Ntaios, George
A1 Foerch, Christian
A1 Spanaus, Katharina
A1 Von Eckardstein, Arnold
A1 Dawson, Jesse
A1 Katan, Mira
YR 2023
UL http://medrxiv.org/content/early/2023/09/29/2023.09.28.23296282.abstract
AB Background Prolonged cardiac monitoring (PCM) increases atrial fibrillation detection after stroke (AFDAS) but access is limited. We aimed to assess the utility of midregional pro-atrial natriuretic peptide (MR-proANP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) to identify people who are unlikely to have AFDAS and improve healthcare resource allocation for PCM..Methods We analysed people from the BIOSIGNAL (Biomarker Signature of Stroke Aetiology) study with ischaemic stroke, no known AF and ≥3 days cardiac monitoring. External validation was in the PRECISE (Preventing Recurrent Cardioembolic Stroke: Right Approach, Right Patient) study of 28-days cardiac monitoring after stroke.The main outcome is no AFDAS. We assessed the discriminatory value of MR-proANP and NT-proBNP combined with clinical variables to identify people with no AFDAS. We determined the net reduction in people who would undergo PCM using the models with 15% AFDAS threshold probability.Results We included 621 people from BIOSIGNAL. The clinical model included age, National Institutes of Health Stroke Scale score, lipid-lowering therapy, creatinine and smoking status. The AUROC was 0.68 (95%CI 0.62-0.74) with clinical variables, which improved with log10MR-proANP (0.72,0.66-0.78;p=0.001) or log10NT-proBNP (0.71,0.65-0.77;p=0.009). Performance was similar for log10MR-proANP versus log10NT-proBNP (p=0.28).In 239 people from PRECISE, the AUROC for clinical variables was 0.68 (0.59-0.76), which improved with log10NT-proBNP (0.73,0.65-0.82;p<0.001) or log10MR-proANP (0.79,0.72-0.86;p<0.001). Performance was better with log10MR-proANP versus log10NT-proBNP (p=0.03).The models could reduce the number who would undergo PCM by 30% (clinical+log10MR-proANP), 27% (clinical+log10NT-proBNP) or 20% (clinical).Conclusions MR-proANP and NT-proBNP help classify people who are unlikely to have AFDAS and could reduce the number who need PCM by 30%.Competing Interest StatementDisclosures AC has received research grants from Pfizer and honoraria from BMS, Pfizer, AstraZeneca and Boeheringer Ingelheim. JD has received speaker fees from Pfizer, BMS, Bayer, Boeringher Ingelheim, Daiichi Sankyo, research funding from Pfizer and BMS; and serves on an advisory board for Metronic. TQ has received investigator initiated research funding from BMS and Pfizer for research on atrial fibrillation. RC has received honoraria for speaking from AstraZeneca and advisory board fees from Bayer. KDs employer, the University of Glasgow, has been remunerated by AstraZeneca for work relating to clinical trials. KD has received speaker honoraria from AstraZeneca and Radcliffe Cardiology, has served on an advisory board for Us2.ai and Bayer AG, served on a clinical endpoint committee for Bayer AG, and has received research grant support from AstraZeneca, Roche and Boehringer Ingelheim, outside the submitted work. CWC is a member of the iSchemaView (Menlo Park, CA, USA) Medical and Scientific Advisory Board. CF reports a patent Use of GFAP for identification of intracerebral Hemorrhage US20150247867 licensed to Banyan Biomarkers. MA has received personal fees from Amgen, Bayer, Bristol-Myers Squibb, Covidien, Daiichi-Sankyo, Medtronic, Nestle Health Science, AstraZeneca, and Portola, and has received grants from Swiss National Science Foundation and Swiss Heart Foundation. GMDM has received an unrestricted grant from B.R.A.H.M.S. for the CoRISK study in 2012. GK has received grants from Swiss Heart Foundation, Swiss National Foundation, Swiss Parkinson Foundation, Bangerter-Rhyner Stiftung, and Deutschschweizer Logopadinnen und Logopadenverband, and has served on the advisory boards of Bayer, Bial, Medtronic, and Alexion. AvE has received personal fees from Amgen and Sanofi. MK has received grants from the Swiss National Science Foundation, Swiss Heart Foundation, and Baasch Medicus Foundation; has received nonfinancial support from B.R.A.H.M.S., and has served on the advisory board of Medtronic. The remaining authors have nothing to disclose.Clinical TrialNCT02274727Funding StatementSources of Funding The BIOSIGNAL study was supported by the Swiss National Science Foundation (grant 142422), the Swiss Heart Foundation, the USZ-Foundation and the Baasch Medicus Foundation. The kits for the measurement of MR-proANP in the BIOSIGNAL study were provided by B.R.A.H.M.S. Gmbh, which produces the assay. However, B.R.A.H.M.S. was not involved in the study design or analyses. The PRECISE study is supported by the Heart Research UK (Scotland) Grant (RG2700/21/24), the Royal College of Physicians and Surgeons of Glasgow Ritchie Trust Research Award, the Mason Medical Research Trust and the University of Glasgow. Measurement of NT-proBNP levels was supported by funding from a Pfizer Quality Improvement Grant (67452629).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The BIOSIGNAL study was approved by the local Ethics Committees of participating centres (main centre: Cantonal Ethics Commission of Zurich, BASEC-Nr. PB_2016-00672) and conducted according to the Declaration of Helsinki. All participants, or their welfare guardians, provided written informed consent. The PRECISE study is approved by the West of Scotland Research Ethics Committee 3 and all participants provide written, informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesEthical approval is not in place to share data from study participants.